Research advances of factors and mechanisms for therapeutic efficacy of rituximab for primary membranous nephropathy
Primary membranous nephropathy (PMN) is a kidney-specific autoimmune disease mediated by autoantibodies. Although rituximab (RTX) has been widely applied as a first-line treatment for PMN, 20%-40% patients are non-responsive to RTX. High disease activity, severe renal lesions and low RTX bioavailabi...
Saved in:
Main Authors: | , |
---|---|
Format: | Book |
Published: |
Editorial Department of Journal of Clinical Nephrology,
2024-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Internet
Connect to this object online.3rd Floor Main Library
Call Number: |
A1234.567 |
---|---|
Copy 1 | Available |